ESMO 2022 - TROPiCS-02: Final results phase III study in MBC

MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC

DESTINY-Breast04 trial in HER2-low unresectable and/or metastatic breast cancer

AACR 2022: Recurrent NIB May Not Always Be Related to the Primary Lesion

AACR 2022: AI Model Can Help Predict Adverse Events from New Drug Combinations